3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Yisheng US Biopharma, Inc. is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Rabin-Pappas syndrome | Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium) | Des.TrialAppr. |
| hepatocellular carcinoma | Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium) | Des.TrialAppr. |
| malignant pancreatic neoplasm | Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Polyinosinic-polycyidylic acid, kanamycin and calcium) | Des.TrialAppr. |
| rabies | Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium) | Des.TrialAppr. |
| radius fracture | Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio